Startup Corsera Health aims to bring preventive heart medicine to the masses BioPharma Dive Nawigacja wpisu Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome – Biogen Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate – Yahoo Finance
